Oncology Corporate Profile
MabVax Therapeutics Holdings, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma ready for Phase II clinical development.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|MVT-5873 (+ chemotherapy)||monoclonal antibody||Pancreatic cancer||I|
|MVT-5873||monoclonal antibody||Pancreatic cancer||I|
|MVT-1075||radioimmunotherapy||Small Cell Lung Cancer (SCLC)||I|
|HuMab 5B1||antibody drug conjugates (ADC)||Pancreatic cancer||Preclinical|
View additional information on product candidates here »